STKH — Steakholder Foods Ltd.
Is STKH overbought or oversold? Here is the current MarketMoodz read.
Steakholder Foods Ltd. (STKH) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Consumer Defensive name (Packaged Foods) last closed at $1.82. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.82
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorConsumer Defensive
- IndustryPackaged Foods
See all oversold Consumer Defensive stocks →
AI analysis
Steakholder Foods Ltd. (STKH) is an early-stage cultured/alternative-protein company with attractive long-term structural demand but substantial near-term execution and financing risks. The company’s technology and potential partnership pathways offer upside if pilot-scale production and cost reductions proceed on plan; however, the absence of detailed recent public filings and modest social/research coverage increases uncertainty. Key near-term drivers are demonstration of scalable manufacturing, regulatory clarity, and any commercial offtake or strategic partner announcements. Balance between upside from commercialization milestones and high dilution/execution risk supports a cautious stance with close monitoring of cash runway, operational metrics, and concrete commercial progress.
Key factors
- Early-stage alternative-protein / cell-cultured meat positioning with long-term market opportunity if cost and scale hurdles are overcome
- Technology and IP focus that could deliver differentiation in texture and formulation versus plant-based competitors
- Sector-level tailwinds for protein innovation and renewed reinvestment in packaged foods that can benefit partnerships or offtake deals
- Limited public financial disclosure and apparent reliance on financing rounds increases sensitivity to capital markets and dilution risk
- Market sentiment currently risk-on toward growth, which may support share stability near short-term catalysts (earnings, pilot partnerships)
- Potential for meaningful upside if pilot production scales, cost-per-unit declines, or commercial supply agreements are announced
Risks
- High cash burn and unclear liquidity runway absent recent EDGAR filing detail or visible revenue traction
- Execution risk on scaling cell-cultured production — manufacturing, yield, contamination and cost-per-kilogram challenges
- Regulatory approval and labeling uncertainty in key markets could delay commercialization and limit addressable market
- Significant dilution risk from future financing rounds that can materially depress per-share value
- Competitive pressure from well-funded incumbents in alternative proteins, large food companies, and plant-based producers
- Low social/research signal and limited analyst coverage increases volatility and makes market moves prone to rumor-driven swings
See today's live rating, score and targets
Members see the live hourly rating for STKH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.